Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.76 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 0.99 |
| ▸ | GAA | P10253 | 2/20 | 0.99 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.97 |
| ▸ | MMP1 | P03956 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL30822976 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL29359605 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL359364 | 1.00 | PAX8 (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL29363805 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL4450369 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL663859 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL4033 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL31175855 | 0.99 | PAX8 (0.99) | PAX8NCOA3GLAGAAKDM4E | |
| Irinotecan SCHEMBL16447653 | 0.99 | GLA (1.00) | PAX8NCOA3GLAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447150-B2 | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-21 | — | — | US | claimed |
| US-20240254226-A1 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-01 | — | — | US | claimed |
| EP-4353265-A1 | METHOD FOR TREATING CANCER THROUGH COMBINATION OF CD47 INHIBITOR, IMMUNE CHECKPOINT INHIBITOR, AND STANDARD THERAPY | ONO Pharmaceutical Co., Ltd. (JP) | 2024-04-17 | — | — | EP | claimed |
| CN-117460534-A | Methods of cancer treatment based on combinations of CD47 inhibitory substances, immune checkpoint inhibitory substances and standard therapies | 小野药品工业株式会社 | 2024-01-26 | — | — | CN | claimed |
| US-20230390303-A1 | CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-07 | — | — | US | claimed |
| EP-4245301-A1 | CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO Pharmaceutical Co., Ltd. (JP) | 2023-09-20 | — | — | EP | claimed |
| WO-2022260132-A1 | METHOD FOR TREATING CANCER THROUGH COMBINATION OF CD47 INHIBITOR, IMMUNE CHECKPOINT INHIBITOR, AND STANDARD THERAPY | 小野薬品工業株式会社 | 2022-12-15 | — | — | WO | claimed |
| WO-2022102731-A1 | CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | 小野薬品工業株式会社 | 2022-05-19 | — | — | WO | claimed |
| US-20220008421-A1 | TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | claimed |
| EP-3888648-A1 | TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY | ONO Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | claimed |
| EP-2979701-B1 | ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-08-26 | — | — | EP | claimed |
| EP-2979700-B1 | ANTITUMOR AGENT INCLUDING LOW DOSE IRINOTECAN HYDROCHLORIDE HYDRATE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-09-26 | — | — | EP | claimed |
| US-9616082-B2 | Antitumor agent including irinotecan hydrochloride hydrate | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-11 | — | — | US | claimed |
| US-9616081-B2 | Antitumor agent including low-dose irinotecan hydrochloride hydrate | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-11 | — | — | US | claimed |
| US-20160082031-A1 | ANTITUMOR AGENT INCLUDING LOW-DOSE IRINOTECAN HYDROCHLORIDE HYDRATE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-24 | — | — | US | claimed |
| US-20160045530-A1 | ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-02-18 | — | — | US | claimed |
| EP-2979701-A1 | ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-02-03 | — | — | EP | claimed |
| EP-2979700-A1 | LOW-DOSE ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-02-03 | — | — | EP | claimed |
| US-12577307-B2 | Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor | GENENTECH, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577307-B2 | Method and medicament for treating cancer unresponsive to PD-1/PD-L1 signaling inhibitor | PDCD1, CD274, PDCD1LG2 | TOP1 898/4885PAX8 482/4885NCOA3 3650/4885 |
| US-20230390303-A1 | CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | CD274, PTGER4, PDCD1 | TOP1 743/4885PAX8 2003/4885NCOA3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.